Research Tools Catalog

Modified WIBR3 Human ES cell line with PINK1 Q129X mutation. This line was generated as part of the iSCORE-PD (Isogenic Stem Cell Collection to Research Parkinson’s Disease) collection created through a collaboration between the Soldner Lab, Albert Einstein College of Medicine, Hockemeyer Lab, University of California, Berkeley, Bateup Lab, University of California, Berkeley, and Rio Lab, University of California, Berkeley, and developed under the Aligning Science Across Parkinson’s (ASAP) initiative. 

Modified WIBR3 Human ES cell line with DJ-1 Exon 1-5 deletion. This line was generated as part of the iSCORE-PD (Isogenic Stem Cell Collection to Research Parkinson’s Disease) collection created through a collaboration between the Soldner Lab, Albert Einstein College of Medicine, Hockemeyer Lab, University of California, Berkeley, Bateup Lab, University of California, Berkeley, and Rio Lab, University of California, Berkeley, and developed under the Aligning Science Across Parkinson’s (ASAP) initiative.

Modified WIBR3 Human ES cell line with FBXO7 Frameshift mutation. This line was generated as part of the iSCORE-PD (Isogenic Stem Cell Collection to Research Parkinson’s Disease) collection created through a collaboration between the Soldner Lab, Albert Einstein College of Medicine, Hockemeyer Lab, University of California, Berkeley, Bateup Lab, University of California, Berkeley, and Rio Lab, University of California, Berkeley, and developed under the Aligning Science Across Parkinson’s (ASAP) initiative. 

Estimated Availability: Q3 2026

Modified WIBR3 Human ES cell line with FBXO7 R498X mutation. This line was generated as part of the iSCORE-PD (Isogenic Stem Cell Collection to Research Parkinson’s Disease) collection created through a collaboration between the Soldner Lab, Albert Einstein College of Medicine, Hockemeyer Lab, University of California, Berkeley, Bateup Lab, University of California, Berkeley, and Rio Lab, University of California, Berkeley, and developed under the Aligning Science Across Parkinson’s (ASAP) initiative. 

Estimated Availability: Q3 2026

Modified WIBR3 Human ES cell line with DNAJC6 Frameshift mutation. This line was generated as part of the iSCORE-PD (Isogenic Stem Cell Collection to Research Parkinson’s Disease) collection created through a collaboration between the Soldner Lab, Albert Einstein College of Medicine, Hockemeyer Lab, University of California, Berkeley, Bateup Lab, University of California, Berkeley, and Rio Lab, University of California, Berkeley, and developed under the Aligning Science Across Parkinson’s (ASAP) initiative. 

Estimated Availability: Q3 2026

Modified WIBR3 Human ES cell line with DNAJC6 Splice Variant mutation. This line was generated as part of the iSCORE-PD (Isogenic Stem Cell Collection to Research Parkinson’s Disease) collection created through a collaboration between the Soldner Lab, Albert Einstein College of Medicine, Hockemeyer Lab, University of California, Berkeley, Bateup Lab, University of California, Berkeley, and Rio Lab, University of California, Berkeley, and developed under the Aligning Science Across Parkinson’s (ASAP) initiative. 

Estimated Availability: Q3 2026

KOLF2.1J human iPSC line with CRISPR-engineered mutations in TMEM175, including 

• -Q65P (heterozygous and homozygous) - in development, est late 2025
• -M393T (heterozygous and homozygous)
• -DOX-NGN2 + TMEM192-HA + Knockout (heterozygous and homozygous) - in development, est late 2026

These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative. Cell line development is also supported by MJFF Targets to Therapies (T2T) Initiative. 

KOLF2.1J human iPSC line with CRISPR-engineered mutations in SNCA, including

• -A30P (heterozygous and homozygous)
• -A53T (heterozygous and homozygous)
• -E46K (heterozygous and homozygous)
• -DOX-NGN2 + TMEM192-HA + A53T (heterozygous and homozygous) - in development, est late 2026

These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative. Cell line development is also supported by MJFF Targets to Therapies (T2T) Initiative. 

Magnetic bead-conjugated rabbit monoclonal antibody directed against human TMEM192 for immunoprecipitation of lysosomes. An unconjugated version of this antibody is also available. This antibody was generated by Dr. Dario Alessi at the University of Dundee and deposited through the MJFF Sponsored Tools Program as part of the Aligning Science Across Parkinson’s (ASAP) Initiative. For 500uL and 1mL aliquot sizes, use MJFF discount code MJFFAB. Custom orders are recommended if volume needs exceed 1mL. 

Inducible MCI-PARK (iMCI-PARK) mice, based on the ESR-NDUFS2 strain described by Fernández-Agüera, 2015, were generated by crossing mice carrying a floxed allele of mouse Ndufs2 with mice that broadly express tamoxifen-inducible cre recombinase (Tg(CAG-cre/Esr1*)5Amc that result in a conditional, body-wide knock-out of Ndufs2 following tamoxifen induction. Model was originally designed by deleting Ndufs2 only from dopaminergic neurons by D. James Surmeier at Northwestern University and made available through the MJFF Sponsored Tools Program as part of the Aligning Science Across Parkinson’s (ASAP) Initiative. RRID:IMSR_JAX:038571